Navigation Links
Cardium Receives Preliminary Notification of Inclusion in the Russell 3000(R) Index and Russell Global(R) Index

SAN DIEGO, June 17 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced it is scheduled to join the broad-market Russell 3000 Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 26, 2009 according to a preliminary list of additions posted on


Annual reconstitution of Russell's U.S. indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization. Membership in the Russell 3000, which remains in place for one year, also means automatic inclusion in the small-cap Russell 2000 Index as well as the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes. The Russell 3000 also serves as the U.S. component to the Russell Global Index, which Russell launched in 2007.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. Approximately $4 trillion in assets are currently benchmarked to the Russell indexes. These investment tools originated from Russell's multi-manager investment business in the early 1980s when the company saw the need for a more objective, market-driven set of benchmarks in order to evaluate outside investment managers. Total returns data for the Russell 3000 and other Russell Indexes is available at

About Russell

Russell Investments provides strategic advice, world-class implementation, state-of-the-art performance benchmarks and a range of institutional-quality investment products. Russell has $136 billion in assets under management as of March 31, 2009, and serves individual, institutional and advisor clients in more than 40 countries. Founded in 1936, Russell is a subsidiary of The Northwestern Mutual Life Insurance Company.

About Cardium

Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies, Inc. and the Tissue Repair Company, are medical technology companies primarily focused on the development, manufacture and sale of innovative therapeutic products and devices for cardiovascular, ischemic and related indications.

Cardium's InnerCool Therapies subsidiary is a San Diego-based medical technology company in the emerging field of temperature modulation therapy to rapidly and controllably cool the body in order to reduce cell death and damage following acute ischemic events such as cardiac arrest or stroke, and to potentially lessen or prevent associated injuries such as adverse neurological outcomes. For more information about Cardium's InnerCool subsidiary and patient temperature modulation, including InnerCool's new RapidBlue(TM) System, which recently received FDA clearance, and its CoolBlue(TM) System, please visit

Cardium also has two biologic candidates in clinical development. Cardium's Tissue Repair Company subsidiary (TRC) is focused on the development of growth factor therapeutics for the treatment of severe chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-B (PDGF-B). Excellarate(TM) is initially being developed to be administered once or twice for the potential treatment of non-healing diabetic foot ulcers. Other potential applications for TRC's Gene Activated Matrix(TM) (GAM) technology include therapeutic angiogenesis (cardiovascular ischemia, peripheral arterial disease) and orthopedic products, including hard tissue (bone) and soft tissue (ligament, tendon, cartilage) repair. GAM technology can also be applied to a number of other approaches benefiting from sustained localized release of therapeutic proteins and other agents. For more information about Cardium's Tissue Repair Company subsidiary, please visit

Cardium's Generx product candidate (alferminogene tadenovec, Ad5FGF-4) is a DNA-based growth factor therapeutic designed for use by interventional cardiologists as a potential one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina. For more information about Cardium Therapeutics and its businesses, products and therapeutic candidates, please visit or view its most recent annual report on Form 10-K and other reports as filed with the Securities and Exchange Commission and available on the company's website.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward-looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that inclusion in the Russell 3000 Index and Russell Global Index will broaden our investor exposure, or otherwise benefit Cardium or its stock, that our products and product candidates will be successfully advanced and will prove to be sufficiently safe and effective, or that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and therapeutic hypothermia devices and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2009 Cardium Therapeutics, Inc. All rights reserved.

For Terms of Use Privacy Policy, please visit

Cardium Therapeutics(TM) and Generx(R) are trademarks of Cardium Therapeutics, Inc.

Tissue Repair(TM), Gene Activated Matrix(TM), GAM(TM), and Excellarate(TM)

are trademarks of Tissue Repair Company.

InnerCool Therapies(R), InnerCool(R), RapidBlue(TM) and CoolBlue(TM) are trademarks of InnerCool Therapies, Inc.

Other trademarks are the property of their respective owners.

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting
2. Cardium Reports on First Quarter 2009 Financial Results and Recent Developments
3. Cardium Reports on New Excellarate(TM) Product Formulations to Expand Commercialization Potential Into Multiple Wound Healing Applications
4. Cardium Provides Update Regarding Exchange Listing Compliance Plan Accepted by NYSE Amex
5. Cardiums InnerCool Announces Journal of Neurotrauma Highlights Hypothermia Therapys Role in Post Cardiac Arrest, and Traumatic Brain and Spinal Cord Injury Patients
6. Cardium Reports on Recent Highlights, Financial Results and 2009 Outlook
7. Cardiums Exchange Listing Compliance Plan Accepted by NYSE Alternext US
8. Cardiums InnerCool Reports on Expanding Use of Therapeutic Hypothermia
9. Cardiums InnerCool Announces Launch of New Enhanced Website
10. Cardium Reports on Exchange Listing With NYSE Alternext US
11. Cardium Reports on New York Citys Adoption of Therapeutic Cooling Protocols for Cardiac Arrest Patients
Post Your Comments:
(Date:11/29/2015)... ... 2015 , ... Doctors who missed a case of mesothelioma in a 70-year-old ... and push for a diagnosis, especially in people exposed to asbestos. Surviving Mesothelioma has ... it now. , Researchers at Gifu Prefectural Tajimi Hospital in Japan say ...
(Date:11/28/2015)... ... November 28, 2015 , ... Safe storage for contraceptive devices may not always ... Lakewood, New Jersey and the other from Bradley Beach, New Jersey, there is an ... expense of having to replace NuvaRings more often than necessary. As such, it affords ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... According to ... the recent 2015 American Dental Association meeting in Washington D.C. revolved around the fact ... a patient’s overall health. The talk stressed the link between periodontal disease (more commonly ...
(Date:11/27/2015)... ... November 27, 2015 , ... An inventor, ... to dispense prescription medications at home, so he invented the patent-pending ELECTRONIC M.D. ... dispense prescription medications. In doing so, it could help to prevent potential overdose ...
(Date:11/27/2015)... ANGELES, CA (PRWEB) , ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating ... of 30 (see Table 1-1 ). More than 3.7 billion people under the ... virus type 1 (HSV-1), according to WHO's first global estimates of HSV-1 infection . ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... November 27, 2015 Une ... photodynamique au Bremachlorin contre le cancer avancé. ... à combiner l,immunothérapie au traitement photodynamique au Bremachlorin ... Une nouvelle approche consistant à combiner ... cancer avancé.    Clinical Cancer ...
(Date:11/27/2015)... , Nov. 27, 2015  Lannett Company, Inc. ... has completed the acquisition of Kremers Urban Pharmaceuticals ... of global biopharmaceuticals company UCB S.A. (Euronext: UCB). ... Lannett has acquired KU from UCB for total ... adjustments, including a customary working capital adjustment, a ...
(Date:11/26/2015)... , November 27, 2015 ... --> --> ... emergency response system (PERS) market ... for 5 years with APAC ... expected to see a high ...
Breaking Medicine Technology: